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Abstract
Background: Myocardial infarction-related cardiogenic shock is frequently complicated by acute kidney injury. We
examined the influence of acute kidney injury treated with renal replacement therapy (AKI-RRT) on risk of chronic
dialysis and mortality, and assessed the role of comorbidity in patients with cardiogenic shock.
Methods: In this Danish cohort study conducted during 2005–2012, we used population-based medical registries
to identify patients diagnosed with first-time myocardial infarction-related cardiogenic shock and assessed their
AKI-RRT status. We computed the in-hospital mortality risk and adjusted relative risk. For hospital survivors, we
computed 5-year cumulative risk of chronic dialysis accounting for competing risk of death. Mortality after
discharge was computed with use of Kaplan-Meier methods. We computed 5-year hazard ratios for chronic dialysis
and death after discharge, comparing AKI-RRT with non-AKI-RRT patients using a propensity score-adjusted Cox
regression model.
Results: We identified 5079 patients with cardiogenic shock, among whom 13 % had AKI-RRT. The in-hospital
mortality was 62 % for AKI-RRT patients, and 36 % for non-AKI-RRT patients. AKI-RRT remained associated with
increased in-hospital mortality after adjustment for confounders (relative risk = 1.70, 95 % confidence interval (CI):
1.59–1.81). Among the 3059 hospital survivors, the 5-year risk of chronic dialysis was 11 % (95 % CI: 8–16 %) for
AKI-RRT patients, and 1 % (95 % CI: 0.5–1 %) for non-AKI-RRT patients (adjusted hazard ratio: 15.9 (95 % CI: 8.7–29.3).
The 5-year mortality was 43 % (95 % CI: 37–53 %) for AKI-RRT patients compared with 29 % (95 % CI: 29–31 %) for
non-AKI-RRT patients. The adjusted 5-year hazard ratio for death was 1.55 (95 % CI: 1.22–1.96) for AKI-RRT patients
compared with non-AKI-RRT patients. In patients with comorbidity, absolute mortality increased while relative
impact of AKI-RRT on mortality decreased.
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Conclusion: AKI-RRT following myocardial infarction-related cardiogenic shock predicted elevated short-term
mortality and long-term risk of chronic dialysis and mortality. The impact of AKI-RRT declined with increasing
comorbidity suggesting that intensive treatment of AKI-RRT should be accompanied with optimized treatment of
comorbidity when possible.
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Background
Despite considerable improvement in treatment, acute
myocardial infarction (MI) remains a leading cause of
death worldwide [1, 2]. The predominant cause of death
in patients hospitalized for MI is cardiogenic shock [3,
4]. The risk of this complication is approximately 5–9 %
[3, 5–7]. Subsequent in-hospital mortality is as high as
45–65 % [4, 6], i.e., almost ten times higher than in MI
patients without cardiogenic shock [4, 8, 9].
Acute kidney injury (AKI) is defined as an abrupt
decrease in kidney function, ranging from mild kidney
dysfunction to severe AKI with need for renal replacement
therapy (RRT) [10]. AKI is a complication observed in half
of patients with MI-related cardiogenic shock and is asso-
ciated with a marked elevation of in-hospital mortality risk
[11, 12]. In a prospective single-center study, 25 % of
cardiogenic shock patients with AKI required dialysis [12],
which was associated with an excess in-hospital mortality
risk of 16 % compared with patients without need for dia-
lysis (62 % vs. 46 %) [12]. However, the clinical significance
of AKI treated with RRT (AKI-RRT) for long-term mor-
tality following MI-related cardiogenic shock and the in-
fluence of comorbidity are unknown.
Our aim was to examine the prognostic importance of
AKI-RRT with regard to mortality in-hospital and up to
5 years after first-time MI-related cardiogenic shock.
Furthermore, we assessed the influence of AKI-RRT in
subgroups stratified by comorbid conditions among
patients with MI-related cardiogenic shock. Finally, we
examined the risk of chronic dialysis after hospitalization
with MI-related cardiogenic shock, and we described




We conducted this nationwide population-based cohort
study using data from medical registries in Denmark.
The Danish National Health Service provides universal
tax-supported health care, guaranteeing free access to
general practitioners and hospitals, and partial reim-
bursement of prescribed medications [13]. The unique
10-digit Danish Civil Personal Registry number, assigned
to all Danish citizens at birth and to residents upon im-
migration, allows unambiguous linkage of registries [14].
First-time myocardial infarction patients with cardiogenic
shock
We used the Danish National Patient Registry to identify
all persons with a first-time admission for MI-related
cardiogenic shock from 2005 through 2012. The Danish
National Patient Registry contains data on all non-
psychiatric hospital admissions since 1977 and on all
hospital outpatient specialist clinic and emergency room
contacts since 1995 [15]. Each admission is assigned one
primary diagnosis code and up to 19 secondary codes
classified according to the International Classification of
Diseases, 8th revision (ICD-8) until the end of 1993 and
10th revision (ICD-10) thereafter [15]. Important compo-
nents of critical care, including dialysis, treatment with
inotropes/vasopressors and mechanical ventilation, have
been coded routinely with high validity since 2005 [16].
The study cohort included only patients with first-time
MI events, i.e., patients without a previous diagnosis of
MI since 1977. The cohort was further restricted to MI
patients with cardiogenic shock, defined either by a con-
current diagnosis code of cardiogenic shock and/or by
medical treatment with inotropes or vasopressors during
the MI admission. Patients treated with inotropes or
vasopressors, but without a diagnosis code for cardio-
genic shock, were excluded if they had a diagnosis code
for septic shock, hypovolemic shock, or shock without
further specification during the admission. A flowchart
of the inclusion and exclusion criteria is provided in
Additional file 1 (Figure e1). The MI admission period
was defined as the initial admission for MI, including
transfers to other departments and hospitals.
Acute kidney injury treated with renal replacement therapy
Data on any treatment with acute RRT during the hos-
pitalization was obtained from the Danish National Pa-
tient Registry, which provides accurate data on treatment
with acute RRT [15]. To restrict the cohort to patients
with first-time dialysis related to the MI under study,
patients with prior RRT treatment for acute or chronic
kidney disease were excluded.
Study outcomes
Information on migration and all-cause mortality was
obtained through linkage to the Danish Civil Registration
System [14]. This registry was established in 1968 and
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contains information on date of birth, residence, immigra-
tion, and vital status, updated daily [14].
We obtained information on causes of death for patients
with MI-related cardiogenic shock from the Danish Regis-
ter of Causes of Death [17]. This registry contains infor-
mation from all Danish death certificates coded according
to the ICD-10 from 1994–2011 [17]. Codes obtained from
the Danish Register of Causes of Death are provided in
Additional file 1 (Table e1).
We obtained data on date of first chronic dialysis
after hospitalization from the Danish National Patient
Register [15].
Covariates
The Danish Civil Registration System was used to obtain
data on the gender and age of patients [14]. Data on
comorbidities were obtained from the Danish National
Patient Registry using primary and secondary inpatient
diagnoses and outpatient hospital diagnoses during a
fixed period of 10 years preceding the current admission
for MI. We included comorbidities that could act as
potential risk factors for AKI-RRT and have a potential
impact on mortality: congestive heart failure, peripheral
vascular disease, cerebrovascular disease, chronic pulmon-
ary disease, hypertension, atrial fibrillation/flutter, venous
thromboembolism, chronic kidney disease, liver disease,
diabetes, obesity, and cancer. All diagnosis codes used in
the study are provided in Additional file 1 (Table e2).
The Danish Health Service Prescription Registry [18]
provided information on filled preadmission prescrip-
tions for angiotensin-converting enzyme (ACE) inhibi-
tors, angiotensin-II antagonists, anti-diabetics, and non-
steroidal anti-inflammatory drugs (NSAIDs). We identi-
fied prescriptions filled within 100 days before the MI
admission because most drugs are sold in packages
containing no more than 100 tablets. The Danish Health
Service Prescription Registry, established in 2004, includes
virtually complete individual-level data on all filled pre-
scriptions for reimbursed drugs in Denmark [18].
We defined diabetes mellitus from its diagnosis code
or filled prescriptions for anti-diabetic drugs within
100 days before the MI admission (Additional file 1:
Table e2) [18]. Coronary arteriography (CAG), percutan-
eous coronary intervention (PCI), and coronary artery
bypass graft (CABG) during admission were identified
from procedure codes in the Danish National Patient
Registry.
Statistical analyses
We tabulated patient characteristics for the entire study
population and for the cohort of patients surviving until
hospital discharge (denoted as hospital survivors), includ-
ing gender, age group, comorbidity, use of medication,
and procedures during admission, according to AKI-RRT
status.
We first calculated the in-hospital mortality risk in
AKI-RRT and non-AKI-RRT patients for all patients
with complete follow-up on their hospitalization for MI,
i.e., patients discharged before the end of the study
period on 31 December 2012. Next, we computed the
propensity score-adjusted relative risk of death during
hospitalization, comparing AKI-RRT patients with
non-AKI-RRT patients, using a generalized linear model
with a log-link function and a binomial error distribution
[19, 20]. We used a propensity score in the adjusted ana-
lysis to include more variables than a standard multivari-
ate analysis would allow [21]. The propensity score was
defined as the probability of developing AKI-RRT during
hospitalization conditioned on the observed baseline
covariates and computed using a logistic regression model
[21]. The covariates included in the propensity score were
gender, age group (<60, 60–69, 70–79, ≥80 years), comor-
bidities (congestive heart failure, peripheral vascular dis-
ease, cerebrovascular disease, chronic pulmonary disease,
hypertension, atrial fibrillation/flutter, venous thrombo-
embolism, chronic kidney disease, liver disease, diabetes
mellitus, cancer, and obesity), use of medications (ACE
inhibitors, angiotensin receptor blockers, NSAIDs), and
PCI or CABG status. The equal distribution of propensity
scores is visualized in Additional file 1 (Figure e2).
We followed hospital survivors for up to 5 years fol-
lowing their hospital discharge date or until death, emi-
gration, or the end of the study period, whichever came
first. We used the 1 minus Kaplan-Meier method to
compute cumulative mortality following hospital dis-
charge. Crude and propensity score-adjusted hazard ra-
tios were computed using a Cox regression model. The
distribution of propensity scores is shown in Additional
file 1 (Figure e3).
To examine the potential differential impact of AKI-
RRT within subgroups, we repeated the Cox regression
analyses stratified by gender, age groups, comorbidity,
PCI or CABG status, and subgroups of MI (ST-elevation
MI (STEMI), non-STEMI, and unspecified MI). We ad-
justed for propensity score. The propensity score calcu-
lated within each subgroup included the same baseline
variables as in the overall propensity score except for the
subgroup variable itself [21].
We computed the cumulative risk of chronic dialysis
after MI admission by AKI-RRT status accounting for
competing risk of death [22]. We visualized the results
graphically as a cumulative incidence plot. Crude and
propensity score-adjusted hazard ratios were computed
with use of a Cox regression model [23].
Proportional hazards assumptions in all of the Cox
regression analyses were assessed graphically by plotting
log(−log(survival function)) against time for patients
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with and without AKI-RRT and were found to be
satisfactory.
For all MI patients surviving until hospital discharge
we tabulated cause of death according to AKI-RRT sta-
tus. The following causes of immediate death occurred
most frequently: cardiovascular disease, kidney disease,
pulmonary disease and cancer.
We used STATA statistical software version 13.1
(StataCorp LP, TX, USA) for all statistical analyses. The
study was approved by the Danish Data Protection
Agency, record number 2014-41-3658. Data in the Danish
registries are available to researchers, and their use does
not require informed consent or ethics approval.
Results
Patient characteristics
We identified 5079 patients admitted with MI-related
cardiogenic shock. The in-hospital study population con-
sisted of 677 (13 %) patients with AKI-RRT and 4417
(87 %) non-AKI-RRT patients. Patient characteristics for
the entire study population are provided in Table 1.
Among the 3059 hospital survivors, 254 (8 %) had AKI-
RRT during their admission while 2805 (92 %) did not.
Patients with AKI-RRT were of similar age as non-AKI-
RRT patients and had more comorbidity (Table 1).
Mortality
Among 677 patients with AKI-RRT, 408 died during ad-
mission, yielding an in-hospital mortality of 62 %, while
1612 out of 4417 patients without AKI-RRT died during
admission, yielding an in-hospital mortality of 36 %. The
corresponding propensity score-adjusted relative risk of
in-hospital death was 1.70 (95 % confidence interval
(CI): 1.59–1.81) for patients with AKI-RRT compared
with non-AKI-RRT patients (Table 2).
Total follow-up time for hospital survivors was 8838
person-years. Six patients without AKI-RRT emigrated
during follow-up. AKI-RRT patients had a median follow-
up time of 2.2 years (interquartile range (IQR): 0.9–
4.6 years) and non-AKI-RRT patients had a median
follow-up time of 3.0 years (IQR: 1.2–5.2 years).
For patients with AKI-RRT, the mortality risks within
30 days, 1 year, and 5 years after discharge were 5 %,
14 %, and 45 %, respectively. For patients without AKI-
RRT the corresponding mortality risks were 3 %, 10 %,
and 29 % (Table 3 and Fig. 1). The propensity score-
adjusted hazard ratio for death within 5 years after
discharge was 1.55 (95 % CI: 1.22–1.96) for patients
with AKI-RRT compared with non-AKI-RRT patients
(Table 3).
The association between AKI-RRT and mortality dif-
fered by gender. Among males, AKI-RRT increased the
5-year mortality risk after 5 years from 26 % to 45 %,
with a corresponding propensity score-adjusted hazard
ratio of 1.85 (95 % CI: 1.41–2.43) (Table 4). Among fe-
males, AKI-RRT increased the 5-year mortality risk from
35 % to 45 %, with a corresponding 5-year propensity
score-adjusted hazard ratio of 1.04 (95 % CI: 0.64–1.68)
(Table 4). Non-AKI-RRT patients with comorbidity had
a higher absolute mortality risk compared to non-AKI-
RRT patients without comorbidity (Table 4). Despite high
mortality in AKI-RRT patients, the relative importance of
AKI-RRT for 5-year mortality was thereby attenuated
among patients with comorbidities (Table 4). This was
most predominant in patients with chronic pulmonary
disease, congestive heart failure, liver disease, and patients
who did not undergo CAG, PCI, or CABG (Table 4).
AKI-RRT patients with STEMI and non-STEMI had a
5-year risk of death of 40 % and 48 %, respectively. The
propensity score-adjusted hazard ratios did not differ be-
tween STEMI (1.70 (95 % CI: 1.17–2.47) and non-STEMI
(1.74 (95 % CI: 1.07–2.83)) (Table 4).
Cardiovascular diseases were leading causes of death
among patients with MI-related cardiogenic shock (61 %
of causes for AKI-RRT patients and 51 % for non-AKI-
RRT patients) (Table 5). Myocardial infarction and
chronic ischemic heart disease were the most influential
individual causes of death comprising each around 20 %
for AKI-RRT patients and 15 % for non-AKI-RRT pa-
tients (Table 5). Chronic kidney disease as cause of death
accounted for 5 % for AKI-RRT patients and 2 % for
non-AKI-RRT patients (Table 5).
Need for chronic dialysis
The 5-year cumulative risk of chronic dialysis after
admission with MI-related cardiogenic shock for AKI-
RRT patients was 11.3 % (95 % CI: 7.6–15.9 %) compared
with 0.9 % (95 % CI: 0.5–1.4 %) for non-AKI-RRT patients
(Table 6 and Fig. 2). The propensity score-adjusted hazard
ratio for need of chronic dialysis after MI-related car-
diogenic shock was 15.9 (95 % CI: 8.7–29.3) for AKI-RRT
patients compared with non-AKI-RRT patients (Table 6).
Discussion
This study demonstrated an almost twofold increase in
in-hospital mortality in cardiogenic shock patients with
AKI-RRT compared with non-AKI-RRT patients. While
no previous studies examined the prognostic impact
after hospital discharge, we found an approximate 50 %
increased mortality up to 5 years after discharge. The
relative impact of AKI-RRT was most pronounced among
younger patients without comorbidity, a finding possibly
explained by the lower absolute mortality in this subgroup
of patients. We found the presence of comorbidities itself
to be associated with a poor prognosis.
AKI-RRT increased the risk of chronic dialysis almost
16 times compared with non-AKI-RRT patients during
the 5-year follow-up and may contribute to the increased
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Table 1 Characteristics of the entire study population and of hospital survivors, by AKI-RRT status
Entire study population Hospital survivors
Clinical featuresa Total No AKI-RRT AKI-RRT Total No AKI-RRT AKI-RRT
n = 5079 (100)b n = 4417 (100)b n = 662 (100)b n = 3059 (100)b n = 2805 (100)b n = 254 (100)b
Sex
Male 3388 (66.7) 2916 (66.0) 472 (71.3) 2164 (70.7) 1979 (70.6) 185 (72.8)
Female 1691 (33.3) 1501 (34.0) 190 (28.7) 895 (29.3) 826 (29.4) 69 (27.2)
Age (years), median (IQR) 71 (62–78) 70 (62–78) 72 (65–77) 68 (60–75) 68 (60–75) 69 (60–74)
Age groups (years)
< 60 1006 (19.8) 898 (20.3) 108 (16.3) 766 (25.0) 703 (25.1) 63 (24.8)
60–69 1435 (28.3) 1247 (28.2) 188 (28.4) 966 (31.6) 886 (31.6) 80 (31.5)
70–79 1724 (34.0) 1440 (32.6) 284 (42.9) 989 (32.3) 899 (32.1) 90 (35.4)
≥ 80 914 (18.0) 832 (18.8) 82 (12.4) 338 (11.1) 317 (11.3) 21 (8.3)
Comorbidities
Congestive heart failure 330 (6.5) 281 (6.4) 49 (7.4) 166 (5.4) 145 (5.2) 21 (8.3)
Peripheral vascular disease 556 (11.0) 475 (10.8) 81 (12.2) 299 (9.8) 268 (9.6) 31 (12.2)
Cerebrovascular disease 585 (11.5) 504 (11.4) 81 (12.2) 307 (10.0) 284 (10.1) 23 (9.1)
Chronic pulmonary disease 531 (10.5) 468 (10.6) 63 (9.5) 257 (8.4) 232 (8.3) 25 (9.8)
Hypertension 1134 (22.3) 962 (21.8) 172 (26.0) 633 (20.7) 559 (19.9) 74 (29.1)
Atrial fibrillation/flutter 393 (7.7) 342 (7.7) 51 (7.7) 185 (6.1) 166 (5.9) 19 (7.5)
Venous thromboembolism 79 (1.6) 69 (1.6) 10 (1.5) 36 (1.2) 31 (1.1) 5 (2.0)
Chronic kidney disease 177 (3.5) 129 (2.9) 48 (7.3) 95 (3.1) 67 (2.4) 28 (11.0)
Liver disease 55 (1.1) 49 (1.1) 6 (0.9) 21 (0.7) 19 (0.7) 2 (0.8)
Diabetes mellitusc 901 (17.7) 756 (17.1) 145 (22.0) 497 (16.3) 441 (15.7) 56 (22.1)
Cancer 436 (8.6) 389 (8.8) 47 (7.1) 214 (7.0) 202 (7.2) 12 (4.7)
Obesity 143 (2.8) 116 (2.6) 27 (4.1) 81 (2.7) 70 (2.5) 11 (4.3)
Medication used
ACE inhibitors 1019 (20.1) 874 (19.8) 145 (21.9) 589 (19.3) 526 (18.8) 63 (24.8)
Angiotensin II antagonists 666 (13.1) 578 (13.1) 88 (13.2) 413 (13.5) 379 (13.5) 34 (13.4)
NSAIDS 654 (12.9) 551 (12.5) 103 (15.6) 383 (12.5) 346 (12.3) 37 (14.6)
In-hospital procedures
CAG 3473 (68.4) 2979 (67.4) 494 (74.6) 2489 (81.4) 2290 (81.6) 199 (78.4)
PCI 1873 (36.9) 1568 (35.5) 305 (46.1) 1185 (38.7) 1065 (38.0) 120 (47.2)
CABG 1520 (29.9) 1334 (30.2) 186 (28.1) 1334 (43.6) 1251 (44.6) 82 (32.7)
a Comorbidities registered as primary or secondary hospital inpatient and outpatient diagnoses within 10 years preceding current admission
b Values are expressed as number (percentage) unless otherwise indicated
c Defined as either a diagnosis code for diabetes or a prescription redemption for anti-diabetics within 100 days before MI admission
d Prescription redemption within 100 days before admission
ACE Angiotensin-converting enzyme, AKI-RRT Acute kidney injury treated with renal replacement therapy, CABG coronary artery bypass graft, CAG Coronary arteri-
ography, IQR inter quartile range, NSAID non-steroidal anti-inflammatory drug, PCI percutaneous coronary arteriography
Table 2 In-hospital mortality by AKI-RRT status
Exposure No. of deaths No. of hospitalized
patientsa
Absolute mortality
risk (95 % CI)
Relative risk (95 % CI)
Crude (95 % CI) Adjustedb (95 % CI)
No AKI-RRT 1612 4417 36 % (35–38) 1 (reference) 1 (reference)
AKI-RRT 408 662 60 % (56–64) 1.69 (1.57–1.81) 1.70 (1.59–1.81)
a Patients hospitalized with myocardial infarction-related cardiogenic shock
b Adjusted using a propensity score based on sex, age group, and presence/absence of congestive heart failure, peripheral vascular disease, cerebrovascular disease,
chronic pulmonary disease, hypertension, venous thromboembolism, atrial fibrillation/flutter, liver disease, chronic kidney disease, diabetes mellitus, obesity, cancer, use
of angiotensin-converting enzyme inhibitors, angiotensin II antagonists, or non-steroidal anti-inflammatory drugs, and percutaneous coronary intervention/coronary
artery bypass graft status
AKI-RRT Acute kidney injury treated with renal replacement therapy, CI confidence interval
Lauridsen et al. Critical Care  (2015) 19:452 Page 5 of 11
long-term mortality among AKI-RRT patients. In ad-
dition, three times as many AKI-RRT patients were regis-
tered with chronic kidney disease as the cause of death
compared with non-AKI-RRT patients.
Not surprisingly, cardiovascular disease explained the
majority of deaths among patients with MI-related car-
diogenic shock.
Existing studies
Consistent with our findings, two previous studies [11, 12]
reported markedly increased in-hospital mortality among
cardiogenic shock patients with AKI compared with car-
diogenic shock patients without AKI. In a cohort study of
97 patients hospitalized with STEMI and cardiogenic
shock, 52 patients (55 %) developed AKI (defined as a
25 % rise in serum creatinine from baseline) [12]. Thirteen
of the 52 patients with AKI (25 %) required dialysis. In-
hospital mortality risk increased with rising AKI severity
from 2 % among patients without AKI, to 46 % among pa-
tients with non-AKI-RRT, and to 62 % among patients
with AKI-RRT [12]. In contrast to our study of patient
data from all Danish hospitals, that study consisted of a
study population admitted to an intensive care unit at a
University Cardiology Center in Italy. No clear inter-
national recommendation exists for initiation of RRT [10],
which may explain the difference in AKI-RRT prevalence
(25 % compared with 13 % in our study).
Another study of 118 patients with cardiogenic shock
following acute coronary syndrome between 1993 and
2000 revealed an AKI risk of 33 %, with an in-hospital
mortality risk of 87 % among patients with AKI and
53 % among patients without AKI [11]. AKI thus remains
a serious complication of cardiogenic shock, with poor in-
hospital outcome despite aggressive interventional reper-
fusion treatments.
Cardiogenic shock has been reported as a complication
in 5–10 % of STEMI cases and in 2–4 % of non-STEMI
cases [24, 25]. Nevertheless, non-STEMI complicated with
cardiogenic shock has been reported to be associated with
higher in-hospital mortality than STEMI complicated with
cardiogenic shock [25], presumably due to more comor-
bidity [26] and more severe coronary artery disease [27].
We did not find any differences in the impact of AKI-RRT
on long-term mortality between subgroups of patients
with non-STEMI and STEMI among MI patients with
cardiogenic shock.
Another Danish cohort study examined the risk of end-
stage renal disease after dialysis-requiring AKI among
107,937 patients admitted to an intensive care unit [28].
Consistent with our results, the cumulative risk of chronic
Table 3 Five-year mortality estimates for patients with and without AKI-RRT following first-time hospital admission with myocardial






Cumulative mortality % (95 % CI) Hazard ratio (95 % CI)
30-day 1-year 5-year Crude Adjustedb
No AKI-RRT 589 2805 2.5 (2.0–3.2) 9.6 (8.5–10.8) 28.9 (26.8–31.1) 1 (reference) 1 (reference)
AKI-RRT 81 254 4.7 (2.7–8.2) 14.2 (10.4–19.3) 44.9 (37.2–53.4) 1.67 (1.32–2.11) 1.55 (1.22–1.96)
a Patients surviving until hospital discharge
b Cox proportional hazards regression model adjusted using a propensity score





















0 1 2 3 4 5
Years since discharge date
Non-AKI-RRT AKI-RRT
Fig. 1 Five-year cumulative mortality by acute kidney injury treated with renal replacement therapy (AKI-RRT) status
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Table 4 Subgroup analysis of 5-year cumulative mortality following first-time admission with myocardial infarction and cardiogenic
shock comparing patients with and without AKI-RRT







Male 479 2164 26.3 (24.0–28.9) 44.7 (36.1–54.3) 1.85 (1.41–2.43)
Female 264 895 34.9 (31.0–39.1) 45.3 (30.2–63.7) 1.04 (0.64–1.68)
Age group (years)
<60 80 766 12.1 (9.3–15.5) 32.4 (20.0–49.8) 3.00 (1.67–5.40)
60–69 185 966 23.0 (19.8–26.6) 30.1 (20.5–44.7) 1.24 (0.76–2.02)
70–79 309 989 37.1 (33.2–41.3) 60.6 (45.5–76.1) 1.47 (0.82–2.57)
≥ 80 169 338 58.7 (51.7–65.7) 77.6 (51.9–95.3) 1.45 (0.82–2.57)
Comorbidities
Congestive heart failure
No 658 2893 27.0 (24.9–29.2) 43.2 (35.2–52.1) 1.64 (1.28–2.11)
Yes 85 166 62.9 (52.9–73.0) 62.3 (36.6–87.6) 0.67 (0.33–1.25)
Peripheral vascular disease
No 613 2760 26.4 (24.3–28.7) 43.5 (25.2–52.7) 1.69 (1.31–2.19)
Yes 130 299 52.5 (44.9–60.4) 55.8 (36.2–77.3) 1.11 (0.33–1.35)
Cerebrovascular disease
No 631 2752 26.8 (24.7–29.1) 42.8 (34.8–51.7) 1.54 (1.20–1.98)
Yes 112 307 50.0 (42.0–58.7) 60.9 (39.6–82.6) 2.23 (1.16–4.28)
Chronic pulmonary disease
No 632 2802 26.6 (24.5–28.8) 46.1 (37.9–55.1) 1.86 (1.45–2.28)
Yes 111 257 52.7 (45.1–60.7) 33.4 (17.3–58.1) 0.56 (0.26–1.21)
Hypertension
No 668 2874 27.8 (25.7–30.0) 42.5 (34.6–51.4) 1.76 (1.33–2.32)
Yes 75 185 47.8 (38.2–58.3) 68.4 (43.5–90.3) 1.18 (0.77–1.80)
Atrial fibrillation
No 629 2938 28.1 (26.1–30.4) 44.4 (36.7–52.9) 1.56 (1.21–2.01)
Yes 74 195 50.1 (40.7–60.3) 70.0 (45.5–90.7) 1.53 (0.79–2.98)
VTE
No 726 3023 28.7 (26.6–30.8) 45.2 (37.3–53.8) 1.60 (1.26–2.03)
Yes 17 36 46.8 (30.1–67.2) 40.0 (11.8–87.4) 1.22 (0.27–5.46)
Chronic kidney disease
No 694 2964 28.0 (25.9–30.2) 41.9 (34.0–50.8) 1.60 (1.24–2.06)
Yes 49 95 67.9 (53.7–81.3) 75.5 (48.5–95.0) 0.94 (0.49–1.79)
Liver disease
No 729 3038 28.6 (26.5–30.8) 44.6 (36.9–53.2) 1.60 (1.26–2.03)
Yes 14 21 70.2 (45.3–91.2) – 0.73 (0.08–6.48)
Diabetes mellitus
No 590 2562 26.8 (24.6–29.1) 42.2 (33.9–51.5) 1.71 (1.31–2.24)
Yes 153 497 41.6 (35.6–48.3) 58.0 (38.7–78.5) 1.22 (0.75–1.99)
Cancer
No 661 2845 27.5 (25.4–29.7) 44.7 (36.8–53.5) 1.62 (1.27–2.07)
Yes 82 214 47.2 (38.8–56.5) 49.2 (23.4–82.2) 1.03 (0.41–2.58)
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dialysis in the study was 8.5 % 91–180 days after admis-
sion and 3.8 % 181 days to 5 years after admission for
dialysis-requiring AKI patients [28]. For patients without
dialysis-requiring AKI, the cumulative risk of chronic
dialysis was 0.1 % 91–180 days after admission and 0.3 %
181 days to 5 years after admission [28].
Potential mechanisms
The mechanisms underlying our findings are not well
understood. Cardiorenal crosstalk in acute MI involves
multifactorial systems and has recently been classified as
a cardiorenal syndrome type 1 [29]. Classical mecha-
nisms include low cardiac output and neurohormonal
activation, release of vasoactive substances resulting in
low renal perfusion, and possible renal ischemia with
AKI [29]. In addition, a marked alteration of immune
and somatic cell signaling has been implicated as an
important contributor to kidney injury [29].
Coronary intervention was frequent in our population,
so the potential for contrast-induced AKI-RRT must be
Table 4 Subgroup analysis of 5-year cumulative mortality following first-time admission with myocardial infarction and cardiogenic
shock comparing patients with and without AKI-RRT (Continued)
Obesity
No 724 2978 28.8 (26.7–31.0) 44.7 (36.9–53.3) 1.60 (1.26–2.03)
Yes 19 81 31.7 (19.9–48.0) 60.2 (17.9–98.7) 1.19 (0.33–4.28)
In-hospital procedures
No CAG, PCI or CABG 264 481 63.1 (57.5–68.6) 51.3 (36.7–67.8) 0.71 (1.26–2.03)
PCI 220 1185 22.7 (19.7–26.2) 46.8 (35.7–60.8) 2.26 (1.57–3.25)
CABG 217 1334 17.5 (15.0–20.2) 37.7 (25.8–52.7) 2.18 (1.38–3.44)
MI subgroups
STEMI 252 1199 25.8 (22.6–29.3) 39.8 (29.3–52.4) 1.70 (1.17–2.47)
Non-STEMI 282 1138 29.2 (26.0–37.8) 47.9 (30.9–68.3) 1.74 (1.07–2.83)
MI unspecified 209 722 33.5 (29.2–38.3) 48.7 (36.0–63.1) 1.27 (0.84–1.91)
a Patients surviving until hospital discharge
b Adjusted for propensity score; the propensity score was calculated within each subgroup including the same baseline variables as in the overall propensity score
except for the subgroup variable itself. The hazard ratio is based on AKI-RRT patients compared with non-AKI-RRT patients
AKI acute kidney injury, AKI-RRT Acute kidney injury treated with renal replacement therapy, CABG coronary arterial bypass graft, CAG coronary angiography,
CI confidence interval, MI myocardial infarction, PCI percutaneous coronary intervention, STEMI ST-elevation myocardial infarction, VTE venous thromboembolism
Table 5 Cause of death among 573 patients dying during follow-up after admission with myocardial infarction-related cardiogenic
shock, by AKI-RRT status
Cause of death (immediate) Totaln = 573 (100)a No AKI-RRTn = 512 (100)a AKI-RRTn = 61 (100)a
Cardiovascular disease 297 (51.8) 260 (50.8) 37 (60.7)
Chronic ischemic disease 23 (4.0) 19 (3.7) 4 (6.6)
Myocardial infarction 88 (15.4) 76 (14.8) 12 (19.7)
Chronic ischemic heart disease 93 (16.2) 82 (16.0) 11 (18.0)
Stroke, ischemic 21 (3.7) 19 (3.7) 2 (3.3)
Other cardiovascular disease 72 (12.5) 64 (12.5) 8 (13.1)
Kidney disease 13 (2.3) 9 (1.8) 4 (6.6)
Chronic kidney disease 12 (2.1) 9 (1.8) 3 (4.9)
Chronic dialysis 0 (0) 0 (0) 0 (0)
Other kidney disease 1 (0.2) 0 (0) 1 (1.6)
Pulmonary disease 54 (9.4) 47 (9.2) 7 (11.5)
Chronic pulmonary disease 37 (6.5) 31 (6.1) 6 (9.8)
Pneumonia 10 (1.8) 9 (1.8) 1 (1.6)
Other respiratory disease 7 (1.2) 7 (1.4) 0 (0)
Cancer 75 (13.1) 73 (14.3) 2 (3.3)
Other cause of death 134 (23.4) 123 (24.0) 11 (18.0)
a Values are expressed as number (percentage)
AKI-RRT Acute kidney injury treated with renal replacement therapy, CI confidence interval
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considered in some patients [30]. Moreover, cardiac
surgery is a known risk factor for development of AKI
among CABG patients [31, 32].
Strengths and limitations
The strengths of our study are its nationwide population-
based cohort design with a well-defined study population
in a country providing tax-financed universal healthcare.
This design minimizes selection bias. In addition, follow-
up for mortality was virtually complete.
The positive predictive value of MI as a primary
diagnosis in the Danish National Patient Registry is
94 % [33], and the positive predictive value of cardio-
genic shock in the Danish National Patient Registry
was found to be equally high in a validation study
[34]. In this study, we included treatment with ino-
tropes/vasopressors that we expect to be a valid proxy
for shock. As the positive predictive value of acute
dialysis is 98 % [16], we assume that the potential for
information bias was small. Any such information bias
is expected to be caused by non-differential misclassifi-
cation, because registration of AKI-RRT is unlikely to be
dependent on mortality status and vice versa. Non-
differential misclassification would have biased the associ-
ation towards the null [35].
A study limitation was lack of creatinine measurements.
Consequently, we could only discriminate between patients
with and without the most severe form of AKI, namely
AKI-RRT.
We have no information about the initiation of RRT
relative to the AKI onset. Delayed initiation of RRT may
be associated with increased mortality among AKI pa-
tients [36], and might have affected our results.
Availability and validity of variables to measure poten-
tial confounding factors are crucial, and unmeasured
and residual confounding must be considered. In obser-
vational studies the impact of uncontrolled confounding
is a major concern [37]. Since the propensity score
method and multivariate adjustment only include known
confounders, the potential for some unmeasured confound-
ing exists. In this study we had no information on smoking
[38], and the potential for residual confounding exists for
the registration of comorbidities, e.g. hypertension.
Heart failure has an impact on long-term-mortality
risk after MI [39, 40], but we lacked data to examine
whether the impact of AKI was influenced by reduced
left ventricular ejection fraction at discharge. However,
even if the data were available, it would be inappropriate
to adjust for a factor in the causal pathway between
AKI-RRT and mortality.
A high absolute mortality risk was seen for subgroups
of patients with chronic pulmonary disease, congestive
heart failure, and liver disease, and those who did not
undergo CAG, PCI, or CABG, independent of AKI-RRT
status. Clinical guidelines recommend that all patients
with MI-related cardiogenic shock are treated with ei-
ther PCI or CABG, if the patient is considered suitable
for the procedure [41, 42]. A potential for confounding
by indication is apparent in this setting when the most
severely affected patients with comorbid diseases are not
offered dialysis or PCI/CABG due to their expected high
mortality.
Since registration of causes of death is based on sub-
jective clinical judgment and first-time and recurrent MI
may to some extent overlap, caution is warranted in the
interpretation of cause of death data.
Clinical significance
AKI-RRT is an important clinical predictor of elevated in-
hospital and long-term mortality among patients with MI-
related cardiogenic shock. Potential causes of increased
Table 6 Need for chronic dialysis for patients with and without AKI-RRT in 5 years following first-time hospital admission with MI-
related cardiogenic shock




Hazard ratio (95 % CI)
Crude Adjustedb
No AKI-RRT 18 2,805 0.9 (0.5–1.4) 1 (reference) 1 (reference)
AKI-RRT 27 254 11.3 (7.6–15.9) 18.7 (10.3–33.9) 15.9 (8.7–29.3)
a Patients surviving until hospital discharge
b Cox proportional hazards regression model adjusted using a propensity score
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Fig. 2 Five-year cumulative risk of chronic dialysis by acute kidney
injury treated with renal replacement therapy (AKI-RRT) status
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mortality may be increased risk of end-stage renal disease
[28] and/or cardiovascular disease [43]. However, more
studies are needed to further examine the cause of
increased long-term mortality, e.g., increased risk of a
second cardiovascular event.
Conclusion
In a large population-based setting, this study found that
AKI-RRT was associated with a substantially increased in-
hospital mortality, 5-year risk of chronic dialysis, and 5-
year mortality. While, comorbidity increased the absolute
mortality risk for all MI patients with cardiogenic shock,
the relative effect of AKI-RRT for 5-year mortality was
most pronounced among patients without comorbidity.
Key messages
 Acute kidney injury treated with renal replacement
therapy (AKI-RRT) is an important predictor of
elevated in-hospital and long-term mortality among
patients with MI-related cardiogenic shock.
 AKI-RRT is associated with substantially increased
risk of chronic dialysis.
 In patients with comorbidity, absolute mortality
increased while relative impact of AKI-RRT on
mortality decreased.
 Future studies are needed to examine the cause of
increased long-term mortality, e.g., increased risk of
a second cardiovascular event.
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